Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 24161606)

1.

Mesenchymal stem cells promote leukaemic cells aberrant phenotype from B-cell acute lymphoblastic leukaemia.

Rodríguez-Pardo VM, Aristizabal JA, Jaimes D, Quijano SM, de los Reyes I, Herrera MV, Solano J, Vernot JP.

Hematol Oncol Stem Cell Ther. 2013 Sep-Dec;6(3-4):89-100. doi: 10.1016/j.hemonc.2013.09.002. Epub 2013 Oct 24.

2.
3.

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.

Lúcio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JJ, San Miguel JF.

Leukemia. 1999 Mar;13(3):419-27.

PMID:
10086733
4.

Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.

Ciudad J, Orfao A, Vidriales B, Macedo A, Martínez A, González M, López-Berges MC, Valverde B, San Miguel JF.

Haematologica. 1998 Dec;83(12):1069-75.

5.

Mesenchymal stromal cells derived from the bone marrow of acute lymphoblastic leukemia patients show altered BMP4 production: correlations with the course of disease.

Vicente López Á, Vázquez García MN, Melen GJ, Entrena Martínez A, Cubillo Moreno I, García-Castro J, Orellana MR, González AG.

PLoS One. 2014 Jan 6;9(1):e84496. doi: 10.1371/journal.pone.0084496. eCollection 2014.

6.

[Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].

Wu M, Sun XF, Xu ZM, Zhang XY, Li FR, Wang XG, Chen XL, Lin HQ, Wen HG, Sun X, Song TW.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Aug;13(4):557-62. Chinese.

PMID:
16129033
7.

Modulation of CD44 in acute lymphoblastic leukemia identifies functional and phenotypic differences of human B cell precursors.

Zittermann SI, Achino BI, Agriello EE, Halperín N, Ramhorst RE, Fainboim L.

Eur J Haematol. 2001 Jun;66(6):377-82.

PMID:
11488936
9.
10.
11.
12.

The CD24 antigen discriminates between pre-B and B cells in human bone marrow.

Duperray C, Boiron JM, Boucheix C, Cantaloube JF, Lavabre-Bertrand T, Attal M, Brochier J, Maraninchi D, Bataille R, Klein B.

J Immunol. 1990 Dec 1;145(11):3678-83.

PMID:
1700990
13.

Human olfactory mucosa multipotent mesenchymal stromal cells promote survival, proliferation, and differentiation of human hematopoietic cells.

Diaz-Solano D, Wittig O, Ayala-Grosso C, Pieruzzini R, Cardier JE.

Stem Cells Dev. 2012 Nov 20;21(17):3187-96. doi: 10.1089/scd.2012.0084. Epub 2012 May 18.

14.

Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors.

Farahat N, Lens D, Zomas A, Morilla R, Matutes E, Catovsky D.

Br J Haematol. 1995 Nov;91(3):640-6.

PMID:
8555067
16.

Mesenchymal stem cells promote a primitive phenotype CD34+c-kit+ in human cord blood-derived hematopoietic stem cells during ex vivo expansion.

Rodríguez-Pardo VM, Vernot JP.

Cell Mol Biol Lett. 2013 Mar;18(1):11-33. doi: 10.2478/s11658-012-0036-1. Epub 2012 Oct 27.

PMID:
23104253
17.

Immunobiologic differences between normal and leukemic human B-cell precursors.

Uckun FM, Ledbetter JA.

Proc Natl Acad Sci U S A. 1988 Nov;85(22):8603-7.

18.

Multiparameter flow cytometric analysis of human fetal bone marrow B cells.

LeBien TW, Wörmann B, Villablanca JG, Law CL, Steinberg LM, Shah VO, Loken MR.

Leukemia. 1990 May;4(5):354-8.

PMID:
1697009
19.

[Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].

Popov AM, Verzhbitskaia TIu, Tsaur GA, Shorikov EV, Savel'ev LI, Tsvirenko SV, Fechina LG.

Klin Lab Diagn. 2010 Aug;(8):36-41. Russian.

PMID:
20886718
20.

[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].

Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y.

Ai Zheng. 2007 Apr;26(4):418-22. Chinese.

PMID:
17430665
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk